Healthcare Services

Diabetic Macular Edema Market to Reach $6B by 2030 at 4.2% CAGR

April 21, 2026April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Diabetic Macular Edema (DME) Market Over The 2026–2030 Period?

The market size for diabetic macular edema (dme) has experienced consistent growth in recent years. It is projected to increase from $4.88 billion in 2025 to $5.09 billion in 2026, at a compound annual growth rate (CAGR) of 4.4%. This historical expansion can be attributed to several factors including the rising prevalence of diabetic eye disease, limited early detection practices, an increase in vision impairment cases, a dependence on hospital-based ophthalmology care, and the growth in diabetes duration.

The market for diabetic macular edema (dme) is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach $6 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.2%. Key factors driving this expansion during the forecast period include progress in biologic treatments, the wider adoption of AI-powered eye screening, the proliferation of specialized eye clinics, a heightened understanding of diabetic eye issues, and the increasing number of elderly individuals with diabetes. Notable trends for this period encompass the growing acceptance of anti-VEGF therapies, the increased utilization of advanced retinal imaging techniques, the enlargement of initiatives for early diagnosis and continuous monitoring, an intensifying emphasis on treatments aimed at preserving vision, and the incorporation of AI in ophthalmic screening.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/diabetic-macular-edema-dme-global-market-report

What Leading Drivers Are Supporting The Diabetic Macular Edema (DME) Market Expansion?

The escalating prevalence of diabetes is anticipated to propel the growth of the diabetic macular edema (DME) market in the coming period. This increasing frequency of diabetes is linked to elements such as sedentary lifestyles, detrimental dietary patterns, escalating obesity figures, an aging demographic, and genetic susceptibility. Diabetes instigates diabetic macular edema through the damage it inflicts on retinal blood vessels, which in turn causes fluid to seep into the macula, leading to swelling. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a public health research institute based in the US, reported that over half a billion people globally were affected by diabetes. This figure is projected to more than double, reaching 1.3 billion individuals by 2050. Therefore, the expanding prevalence of diabetes is a significant impetus behind the expansion of the diabetic macular edema (DME) market.

How Is The Diabetic Macular Edema (DME) Market Segmented Across Different Segment Categories?

The diabetic macular edema (dme) market covered in this report is segmented –

1) By Treatment: Anti-VEGF Therapy, Corticosteroids, Laser Therapy, Surgical Intervention

2) By Disease Stage: Early Stage, Moderate Stage, Advanced Stage

3) By Patient Demographics: Adults, Elderly, Children

4) By Route Of Administration: Intravitreal Injection, Topical, Systemic

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Anti-VEGF Therapy: Monoclonal Antibodies, Recombinant Protein-Based Therapies

2) By Corticosteroids: Intravitreal Steroid Injections, Injectable Sustained-Release Corticosteroids

3) By Laser Therapy: Focal Laser Photocoagulation, Panretinal Photocoagulation

4) By Surgical Intervention: Vitrectomy, Membrane Peeling

What Emerging Trends Are Seen In The Diabetic Macular Edema (DME) Market?

Key companies in the diabetic macular edema (DME) market are increasingly integrating sustained-delivery implant technologies, such as refillable ocular implants, to bolster treatment durability, patient compliance, and the efficiency of vision maintenance. Refillable ocular implants are surgically implanted devices that consistently dispense medication over extended periods, facilitating less frequent dosing, prolonged therapeutic exposure, and a reduced treatment burden. For example, in February 2025, F. Hoffmann-La Roche AG, a biotechnology and pharmaceutical entity based in Switzerland, secured approval for Susvimo (ranibizumab 100 mg/mL delivered via the port delivery platform). This refillable ocular implant is designed for DME treatment, offering continuous ranibizumab delivery, requiring refills as infrequently as twice per year, and demonstrating vision outcomes non-inferior to monthly intravitreal injections. Susvimo notably enhances patient adherence, lowers the injection burden, and aids in sustained vision preservation.

Which Organizations Play A Role In The Diabetic Macular Edema (DME) Market Landscape?

Major companies operating in the diabetic macular edema (dme) market are Roche Holding AG, Bayer AG, Novartis AG, Regeneron Pharmaceuticals, Carl Zeiss Meditec AG, Bausch & Lomb, Carl Zeiss AG, Topcon Corporation, Optos plc, Allergan plc, Chengdu Kanghong Pharmaceutical Group, Kodiak Sciences, Opthea Limited, Oxurion NV, Aerie Pharmaceuticals Inc, Coherus BioSciences, KalVista Pharmaceuticals Inc, Araim Pharmaceuticals Inc, Acucela Inc, Antisense Therapeutics Limited, BCN Peptides SA, Ampio Pharmaceuticals Inc, Oculis SA, ThromboGenics NV, EyePoint Pharmaceuticals Inc.

Get The Full Diabetic Macular Edema (DME) Market Report:

https://www.thebusinessresearchcompany.com/report/diabetic-macular-edema-dme-global-market-report

Which Region Leads The Diabetic Macular Edema (DME) Market In Terms Of Market Share?

North America was the largest region in the diabetic macular edema (DME) market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic macular edema (dme) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Diabetic Macular Edema (DME) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/diabetic-macular-edema-dme-global-market-report

Browse Through More Reports Similar to the Global Diabetic Macular Edema (DME) Market 2026, By The Business Research Company

Macular Degeneration Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Diabetic Retinopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report

Non Proliferative Diabetic Retinopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795